Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Brazil to seek regulatory approval for AstraZeneca vaccine on Jan. 15

Mon, 28th Dec 2020 21:18

(Adds comments by health official and Bolsonaro, background,
details)

By Pedro Fonseca

RIO DE JANEIRO, Dec 28 (Reuters) - Brazil's Fiocruz
biomedical institute will seek approval for the Oxford
University/AstraZeneca vaccine against COVID-19 with
federal health regulator Anvisa on Jan. 15, one of the center's
senior officials said on Monday.

The Jan. 15 date brings a measure of clarity to Brazil's
vaccine rollout, which critics have blasted for falling behind
smaller and poorer peers in Latin America. The AstraZeneca
vaccine represents the Brazilian government's main bet to help
end the world's second-most deadly coronavirus outbreak, after
the United States.

"The final submission of this process, this last milestone,
will be on Jan. 15," Marco Krieger, vice president of health
production and innovation at the Rio de Janeiro-based Fiocruz
institute, told Reuters.

Once seen as a front-runner in the development of a
coronavirus vaccine, the British team has been overtaken by U.S.
drugmaker Pfizer Inc and partner BioNTech,
whose shots are already being used in Britain and the United
States.

Confusion has arisen over the best dosage. Data published
earlier from the British team's Phase 3 trials showed efficacy
was 62% for trial participants given two full doses, but a more
robust 90% for a sub-group given first a half, then a full dose.

Krieger said Fiocruz would apply to Anvisa with a two-dose
regimen, which, despite being less effective, was more widely
tested, including in Brazil.

He said Fiocruz would be applying for a full approval with
Anvisa, rather than an emergency use application. Pfizer, which
is in talks to sell its vaccine to Brazil's federal government,
has said the emergency use application is onerous.

Krieger said the institute would start filling and finishing
1 million doses per week in January, then ramp up to 3 million
weekly doses in early February.

Fiocruz is licensed to receive supplies from AstraZeneca and
eventually produce the vaccine locally. Brazil's federal
government, which has ordered the AstraZeneca vaccine, expects
to receive 100 million doses in the first half of 2021.

Brazilian President Jair Bolsonaro, one of the world's most
prominent coronavirus skeptics, said over the weekend he was not
worried about criticism over the speed of Brazil's vaccine
rollout, saying he felt no pressure.

"Nobody pressures me for anything, I don't give a damn about
it," he said in a video aired on CNN Brasil.

Bolsonaro, who caught the virus in July, has also said he
will not take any COVID-19 vaccine, adding to growing vaccine
skepticism in Brazil.

Brazil now has nearly 7.5 million confirmed cases, and
191,139 deaths from the virus since the outbreak began,
according to data from the Health Ministry.
(Reporting by Pedro Fonseca in Rio de Janeiro
Writing by Gabriel Stargardter
Editing by Brad Haynes and Matthew Lewis)

More News
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.